Which has preferable earnings and valuation, INFU or SBC?

SBC Medical Group has higher revenue and earnings than InfuSystem. SBC Medical Group is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InfuSystem $143.34M 1.85 $870K $0.41 32.10 SBC Medical Group $173.61M 3.02 $50.99M $0.47 10.83

InfuSystem (INFU) Competitors

$13.16 +0.34 (+2.65%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$13.16 0.00 (0.00%)

As of 10/2/2026 07:30 PM Eastern

Compare

INFU vs. LMRI, FLGT, GMRS, SBC, and SRTA

Should you buy InfuSystem stock or one of its competitors? InfuSystem's main competitors and comparable companies include Lumexa Imaging (LMRI), Fulgent Genetics (FLGT), GMR Solutions (GMRS), SBC Medical Group (SBC), and Strata Critical Medical (SRTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does InfuSystem compare to Lumexa Imaging?

InfuSystem (NYSE:INFU) and Lumexa Imaging (NASDAQ:LMRI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

InfuSystem has higher earnings, but lower revenue than Lumexa Imaging. Lumexa Imaging is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$143.34M	1.85	$870K	$0.41	32.10
Lumexa Imaging	$267.73M	3.70	-$47.10M	-$0.49	N/A

InfuSystem presently has a consensus price target of $17.50, suggesting a potential upside of 32.98%. Lumexa Imaging has a consensus price target of $16.00, suggesting a potential upside of 55.04%. Given Lumexa Imaging's stronger consensus rating and higher probable upside, analysts plainly believe Lumexa Imaging is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Lumexa Imaging	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Lumexa Imaging had 4 more articles in the media than InfuSystem. MarketBeat recorded 4 mentions for Lumexa Imaging and 0 mentions for InfuSystem. InfuSystem's average media sentiment score of 0.80 beat Lumexa Imaging's score of 0.67 indicating that InfuSystem is being referred to more favorably in the media.

Company	Overall Sentiment
InfuSystem	Positive
Lumexa Imaging	Positive

71.1% of InfuSystem shares are owned by institutional investors. 10.8% of InfuSystem shares are owned by company insiders. Comparatively, 0.7% of Lumexa Imaging shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

InfuSystem has a net margin of 1.12% compared to Lumexa Imaging's net margin of 0.00%. InfuSystem's return on equity of 2.78% beat Lumexa Imaging's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
Lumexa Imaging	N/A	N/A	N/A

Summary

InfuSystem beats Lumexa Imaging on 9 of the 15 factors compared between the two stocks.

How does InfuSystem compare to Fulgent Genetics?

Fulgent Genetics (NASDAQ:FLGT) and InfuSystem (NYSE:INFU) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

48.1% of Fulgent Genetics shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 36.2% of Fulgent Genetics shares are held by company insiders. Comparatively, 10.8% of InfuSystem shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

InfuSystem has a net margin of 1.12% compared to Fulgent Genetics' net margin of -26.05%. InfuSystem's return on equity of 2.78% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-26.05%	-4.93%	-4.50%
InfuSystem	1.12%	2.78%	1.41%

InfuSystem has lower revenue, but higher earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.83	-$60.51M	-$2.82	N/A
InfuSystem	$143.34M	1.85	$870K	$0.41	32.10

Fulgent Genetics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, InfuSystem has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

In the previous week, Fulgent Genetics had 1 more articles in the media than InfuSystem. MarketBeat recorded 1 mentions for Fulgent Genetics and 0 mentions for InfuSystem. Fulgent Genetics' average media sentiment score of 1.60 beat InfuSystem's score of 0.80 indicating that Fulgent Genetics is being referred to more favorably in the media.

Company	Overall Sentiment
Fulgent Genetics	Very Positive
InfuSystem	Positive

Fulgent Genetics presently has a consensus target price of $27.50, suggesting a potential upside of 28.03%. InfuSystem has a consensus target price of $17.50, suggesting a potential upside of 32.98%. Given InfuSystem's stronger consensus rating and higher possible upside, analysts plainly believe InfuSystem is more favorable than Fulgent Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

InfuSystem beats Fulgent Genetics on 12 of the 16 factors compared between the two stocks.

How does InfuSystem compare to GMR Solutions?

InfuSystem (NYSE:INFU) and GMR Solutions (NYSE:GMRS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

71.1% of InfuSystem shares are owned by institutional investors. 10.8% of InfuSystem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

InfuSystem has higher revenue and earnings than GMR Solutions. GMR Solutions is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$143.34M	1.85	$870K	$0.41	32.10
GMR Solutions	N/A	N/A	N/A	-$1.56	N/A

InfuSystem presently has a consensus target price of $17.50, suggesting a potential upside of 32.98%. GMR Solutions has a consensus target price of $18.78, suggesting a potential upside of 90.64%. Given GMR Solutions' stronger consensus rating and higher possible upside, analysts plainly believe GMR Solutions is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
GMR Solutions	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70

InfuSystem has a net margin of 1.12% compared to GMR Solutions' net margin of 0.00%. InfuSystem's return on equity of 2.78% beat GMR Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
GMR Solutions	N/A	N/A	N/A

In the previous week, GMR Solutions had 4 more articles in the media than InfuSystem. MarketBeat recorded 4 mentions for GMR Solutions and 0 mentions for InfuSystem. InfuSystem's average media sentiment score of 0.80 beat GMR Solutions' score of 0.57 indicating that InfuSystem is being referred to more favorably in the media.

Company	Overall Sentiment
InfuSystem	Positive
GMR Solutions	Positive

Summary

InfuSystem beats GMR Solutions on 9 of the 14 factors compared between the two stocks.

How does InfuSystem compare to SBC Medical Group?

InfuSystem (NYSE:INFU) and SBC Medical Group (NASDAQ:SBC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

InfuSystem presently has a consensus target price of $17.50, suggesting a potential upside of 32.98%. SBC Medical Group has a consensus target price of $8.50, suggesting a potential upside of 66.99%. Given SBC Medical Group's higher probable upside, analysts clearly believe SBC Medical Group is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
SBC Medical Group	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

SBC Medical Group has higher revenue and earnings than InfuSystem. SBC Medical Group is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$143.34M	1.85	$870K	$0.41	32.10
SBC Medical Group	$173.61M	3.02	$50.99M	$0.47	10.83

71.1% of InfuSystem shares are held by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are held by institutional investors. 10.8% of InfuSystem shares are held by insiders. Comparatively, 81.7% of SBC Medical Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, SBC Medical Group had 4 more articles in the media than InfuSystem. MarketBeat recorded 4 mentions for SBC Medical Group and 0 mentions for InfuSystem. InfuSystem's average media sentiment score of 0.80 beat SBC Medical Group's score of 0.19 indicating that InfuSystem is being referred to more favorably in the media.

Company	Overall Sentiment
InfuSystem	Positive
SBC Medical Group	Neutral

InfuSystem has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market. Comparatively, SBC Medical Group has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

SBC Medical Group has a net margin of 27.99% compared to InfuSystem's net margin of 1.12%. SBC Medical Group's return on equity of 18.47% beat InfuSystem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
SBC Medical Group	27.99%	18.47%	13.10%

Summary

SBC Medical Group beats InfuSystem on 10 of the 14 factors compared between the two stocks.

How does InfuSystem compare to Strata Critical Medical?

Strata Critical Medical (NASDAQ:SRTA) and InfuSystem (NYSE:INFU) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Strata Critical Medical has a net margin of 15.71% compared to InfuSystem's net margin of 1.12%. InfuSystem's return on equity of 2.78% beat Strata Critical Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Strata Critical Medical	15.71%	-2.97%	-2.54%
InfuSystem	1.12%	2.78%	1.41%

Strata Critical Medical has higher revenue and earnings than InfuSystem. Strata Critical Medical is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Strata Critical Medical	$197.14M	2.12	$41.35M	-$0.04	N/A
InfuSystem	$143.34M	1.85	$870K	$0.41	32.10

Strata Critical Medical has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market. Comparatively, InfuSystem has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

Strata Critical Medical presently has a consensus price target of $8.00, indicating a potential upside of 69.13%. InfuSystem has a consensus price target of $17.50, indicating a potential upside of 32.98%. Given Strata Critical Medical's stronger consensus rating and higher possible upside, equities research analysts clearly believe Strata Critical Medical is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Strata Critical Medical	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

47.4% of Strata Critical Medical shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 15.5% of Strata Critical Medical shares are owned by insiders. Comparatively, 10.8% of InfuSystem shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, InfuSystem's average media sentiment score of 0.80 beat Strata Critical Medical's score of 0.00 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Overall Sentiment
Strata Critical Medical	Neutral
InfuSystem	Positive

Summary

Strata Critical Medical beats InfuSystem on 9 of the 16 factors compared between the two stocks.

Get InfuSystem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INFU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INFU vs. The Competition

Export

Metric	InfuSystem	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$258.73M	$9.59B	$7.14B	$22.64B
Dividend Yield	N/A	2.61%	2.53%	3.73%
P/E Ratio	219.37	34.21	275.68	27.75
Price / Sales	1.85	5.39	662.25	96.41
Price / Cash	12.79	120.59	77.60	38.88
Price / Book	5.33	5.15	10.93	4.64
Net Income	$870K	$315.68M	$3.51B	$1.08B
7 Day Performance	3.54%	-2.59%	-2.00%	-1.06%
1 Month Performance	8.05%	-3.19%	-6.15%	-5.49%
1 Year Performance	27.03%	7.93%	7.44%	5.13%

InfuSystem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INFU InfuSystem	3.2036 of 5 stars	$13.16 +2.7%	$17.50 +33.0%	+28.8%	$258.73M	$143.34M	219.37	473
LMRI Lumexa Imaging	4.107 of 5 stars	$10.26 +1.1%	$16.00 +55.9%	N/A	$974.68M	$267.73M	N/A	5,019	News Coverage Analyst Upgrade
FLGT Fulgent Genetics	3.4603 of 5 stars	$22.08 -1.3%	$27.50 +24.5%	-6.2%	$615.24M	$322.67M	N/A	1,315	Positive News
GMRS GMR Solutions	4.6151 of 5 stars	$9.85 -1.7%	$18.78 +90.6%	N/A	$541.30M	$5.88B	N/A	34,000
SBC SBC Medical Group	3.9876 of 5 stars	$4.84 -3.8%	$8.50 +75.6%	+20.3%	$497.78M	$175.17M	10.30	863

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:INFU) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InfuSystem (INFU) Competitors

INFU vs. LMRI, FLGT, GMRS, SBC, and SRTA

How does InfuSystem compare to Lumexa Imaging?

Summary

How does InfuSystem compare to Fulgent Genetics?

Summary

How does InfuSystem compare to GMR Solutions?

Summary

How does InfuSystem compare to SBC Medical Group?

Summary

How does InfuSystem compare to Strata Critical Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INFU vs. The Competition

InfuSystem Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InfuSystem (INFU) Competitors

INFU vs. LMRI, FLGT, GMRS, SBC, and SRTA

How does InfuSystem compare to Lumexa Imaging?

Which has stronger valuation & earnings, INFU or LMRI?

Do analysts prefer INFU or LMRI?

Does the media refer more to INFU or LMRI?

Do institutionals & insiders hold more shares of INFU or LMRI?

Is INFU or LMRI more profitable?

Summary

How does InfuSystem compare to Fulgent Genetics?

Do insiders and institutionals believe in FLGT or INFU?

Is FLGT or INFU more profitable?

Which has better valuation and earnings, FLGT or INFU?

Which has more volatility & risk, FLGT or INFU?

Does the media refer more to FLGT or INFU?

Do analysts rate FLGT or INFU?

Summary

How does InfuSystem compare to GMR Solutions?

Do institutionals and insiders hold more shares of INFU or GMRS?

Which has preferable valuation and earnings, INFU or GMRS?

Do analysts recommend INFU or GMRS?

Is INFU or GMRS more profitable?

Does the media favor INFU or GMRS?

Summary

How does InfuSystem compare to SBC Medical Group?

Do analysts recommend INFU or SBC?

Which has preferable earnings and valuation, INFU or SBC?

Do insiders & institutionals hold more shares of INFU or SBC?

Does the media refer more to INFU or SBC?

Which has more volatility & risk, INFU or SBC?

Is INFU or SBC more profitable?

Summary

How does InfuSystem compare to Strata Critical Medical?

Is SRTA or INFU more profitable?

Which has better valuation & earnings, SRTA or INFU?

Which has more volatility & risk, SRTA or INFU?

Do analysts recommend SRTA or INFU?

Do insiders and institutionals believe in SRTA or INFU?

Does the media prefer SRTA or INFU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INFU vs. The Competition

InfuSystem Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools